Niki BioSolutions, Inc. (NIKI) Cash & Equivalents (2017 - 2025)

Niki BioSolutions (NIKI) has 9 years of Cash & Equivalents data on file, last reported at $84890.0 in Q4 2025.

• Quarterly Cash & Equivalents changed N/A year-over-year to $84890.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $84890.0 (changed N/A YoY) and the FY2025 annual result came in at $3.5 million, up 72.18% from the prior year.
• Cash & Equivalents improved to $84890.0 in Q4 2025, from $28313.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $20.1 million in Q2 2021 to a low of $28313.0 in Q3 2025.
• A 5-year average of $4.5 million and a median of $3.0 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 386.63% — and 2022, when it sank 79.74%.
• Tracing NIKI's Cash & Equivalents over 5 years: stood at $8.3 million in 2021, then slumped by 39.32% to $5.0 million in 2022, then plunged by 60.0% to $2.0 million in 2023, then sank by 96.5% to $70276.0 in 2024, then gained by 20.8% to $84890.0 in 2025.
• The last three Cash & Equivalents figures came in at $84890.0 (Q4 2025), $28313.0 (Q3 2025), and $56836.0 (Q2 2025), per Business Quant data.